Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Docetaxel and Gemcitabine in Hormonal Refractory Metastatic Prostate Cancer

This study has been completed.
Sponsor:
Collaborators:
Sanofi
Eli Lilly and Company
Information provided by:
Herlev Hospital
ClinicalTrials.gov Identifier:
NCT00115635
First received: June 23, 2005
Last updated: October 1, 2007
Last verified: October 2007
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2007
  Estimated Primary Completion Date: No date given